Enanta Pharmaceuticals Inc
$ 14.09
-1.05%
04 Dec - close price
- Market Cap 410,866,000 USD
- Current Price $ 14.09
- High / Low $ 14.46 / 13.98
- Stock P/E N/A
- Book Value 3.03
- EPS -3.84
- Next Earning Report 2026-02-09
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.85 %
- 52 Week High 15.34
- 52 Week Low 4.09
About
Enanta Pharmaceuticals Inc. is a targeted biotechnology firm based in Watertown, Massachusetts, specializing in the discovery and development of innovative small molecule therapeutics for viral infections and liver diseases. The company has developed a promising pipeline featuring candidates aimed at hepatitis B and a range of viral pathogens, demonstrating its strong scientific foundation and commitment to addressing critical healthcare needs. With a strategic focus on advancing proprietary programs, Enanta is poised to significantly influence the management of infectious diseases and liver health, offering improved treatment options and patient outcomes in these crucial areas.
Analyst Target Price
$19.12
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-01 | 2025-08-11 | 2025-05-12 | 2025-02-10 | 2024-11-25 | 2024-08-05 | 2024-05-06 | 2024-01-26 | 2023-11-20 | 2023-08-07 | 2023-05-08 | 2023-02-07 |
| Reported EPS | -0.87 | -0.85 | -1.06 | -1.05 | -1.36 | -1.07 | -1.47 | -1.58 | -1.33 | -1.86 | -1.79 | -1.39 |
| Estimated EPS | -1.01 | -0.88 | -1.14 | -1.35 | -0.92 | -1.45 | -1.33 | -1.19 | -2.15 | -2.34 | -1.98 | -1.59 |
| Surprise | 0.14 | 0.03 | 0.08 | 0.3 | -0.44 | 0.38 | -0.14 | -0.39 | 0.82 | 0.48 | 0.19 | 0.2 |
| Surprise Percentage | 13.8614% | 3.4091% | 7.0175% | 22.2222% | -47.8261% | 26.2069% | -10.5263% | -32.7731% | 38.1395% | 20.5128% | 9.596% | 12.5786% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-09 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.7775 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ENTA
2025-11-02 00:00:00
Enanta Pharmaceuticals, Inc. announced a proposed underwritten public offering of $50.0 million of its common stock, with an option for underwriters to purchase an additional $7.5 million. The offering is subject to market conditions, and J.P. Morgan, Jefferies, and Evercore ISI are acting as joint book-running managers. The biotechnology company specializes in small molecule drugs for virology and immunology indications.
2025-10-30 00:00:00
Enanta Pharmaceuticals (NASDAQ:ENTA) shares have plummeted 30% in the last 30 days, resulting in a 7.5% annual decline and raising concerns for investors despite a seemingly low price-to-sales (P/S) ratio of 4.6x. The low P/S ratio is attributed to the company's declining revenue and modest future growth forecasts of 1.7% per year, significantly trailing the biotech industry's projected 132% annual growth. This indicates that shareholders are accepting the low P/S due to anticipated anemic revenue performance.
2025-10-16 20:49:39
Enanta Pharmaceuticals Inc. released positive topline results from its Phase 2b study of zelicapavir, an N-protein inhibitor for acute Respiratory Syncytial Virus (RSV) in high-risk adult outpatients. The drug, which has Fast Track designation from the FDA, showed a consistent safety profile and efficacy in the proof-of-concept trial, which evaluated its antiviral treatment effect using the RiiQ tool. Zelicapavir targets the virus's replication machinery, demonstrating a high barrier to resistance and potency against clinical isolates, differentiating it from RSV fusion inhibitors.
2025-10-16 20:49:36
Enanta Pharmaceuticals Inc. reported positive topline results from its Phase 2b study of zelicapavir, a novel N-protein inhibitor for acute Respiratory Syncytial Virus (RSV) infection in high-risk adult outpatients. The study aimed to inform the design of a Phase 3 study by assessing the antiviral treatment effect on symptoms using the RiiQ tool. Zelicapavir, with FDA Fast Track designation, has shown a consistent safety profile and targets the virus’s replication machinery.
2025-09-03 00:00:00
Enanta Pharmaceuticals' shares have surged 27% recently, but the stock is still down 29% over the past year. Despite a low price-to-sales (P/S) ratio of 3x compared to an industry average of 8.7x, the company faces challenges with declining revenue and negative revenue growth forecasts, which justify its current valuation. Analysts predict a 3.2% annual revenue decrease for Enanta over the next three years, contrasting sharply with the broader biotech industry's projected 119% growth.
2025-06-30 00:00:00
Enanta Pharmaceuticals reported financial results for its fiscal third quarter ended June 30, 2025, with total revenue of $18.3 million primarily from MAVYRET/MAVIRET royalties. The company made significant pipeline progress, completing enrollment in the RSVHR trial for zelicapavir and advancing immunology programs for KIT and STAT6 inhibitors. Enanta also announced that its cash and marketable securities totaled $204.1 million, providing funding into fiscal year 2028.
